Following an extraordinary surge in its share price of more than 200% during January, ImmunityBio now faces the critical task of justifying its elevated market valuation. The biotechnology firm has responded by initiating a pivotal Phase 2 clinical trial, focusing on a chemotherapy-free approach to cancer treatment. This move raises a key question for investors: can this development provide the fundamental support needed for the stock’s recent explosive rally?
The newly launched “ResQ215B” study will evaluate a novel combination therapy for adults with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström macroglobulinemia. A defining feature of this protocol is its avoidance of lymphodepletion through chemotherapy, positioning it as a potential outpatient treatment option.
A Chemotherapy-Free Strategy Gains Momentum
This clinical effort combines the company’s CD19-targeted CAR-NK cell therapy with the drug ANKTIVA and the antibody Rituximab. The ambition is to establish a viable alternative to conventional CAR-T cell therapies, which frequently necessitate intensive and burdensome concomitant treatments.
Management’s confidence is rooted in prior Phase 1 (QUILT-106) study data. In a small cohort of four Waldenström macroglobulinemia patients treated with the non-chemotherapy combination, a disease control rate of 100% was observed. Within this group, two patients achieved a complete remission, which was maintained at 7 and 15 months, respectively. The expanded Phase 2 trial will now enroll adult patients who have relapsed or become refractory after at least two prior lines of therapy.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Regulatory Milestones and Upcoming Catalysts
The trial announcement comes on the heels of a busy start to the year for ImmunityBio. On January 20, the company held a meeting with the U.S. Food and Drug Administration (FDA) concerning a potential label expansion for ANKTIVA in a specific form of bladder cancer. The agency requested additional information but did not mandate new clinical studies. ImmunityBio has committed to submitting the required data within a 30-day window.
Concurrently, the firm secured a regulatory win in the Middle East in January, with Saudi Arabia’s Food and Drug Authority approving ANKTIVA for the treatment of non-muscle invasive bladder cancer. Authorization processes are also advancing in both Europe and the United Kingdom.
The month of February presents crucial deadlines. ImmunityBio must deliver the requested information to the FDA on schedule while continuing to advance its broader clinical pipeline. Market participants will be watching closely to determine whether these operational strides can sustainably underpin the company’s current market capitalization of approximately $6.2 billion.
Ad
ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from February 2 delivers the answer:
The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 2.
ImmunityBio: Buy or sell? Read more here...
